A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.

Trial Details

NCT ID
NCT07082920
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • JNJ-78278343
  • JNJ-95298177
  • JNJ-87189401
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Seattle, Washington, United States|47.60621,-122.33207
  • Manchester, United Kingdom|53.48095,-2.23743

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma of the prostate. Primary small cell carcinoma, carcinoid tumor, neuroendocrine (NE) carcinoma, or large cel…
  • Must have metastatic castration-resistant prostate cancer (mCRPC)
  • PSA must measure at least 2 nanograms per milliliters (ng/mL) at screening
  • Measurable or evaluable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →